Jurek L, Leaune E.
J Am Acad Child Adolesc Psychiatry. 2024 Sep 24:S0890-8567(24)01882-3.
PMID: 39326514
Abstract
The recent article by Riccioni et al.1 entitled "Systematic Review and Meta-Analysis: Reporting and Representation of Race/Ethnicity in 310 Randomized Controlled Trials of Attention-Deficit/Hyperactivity Disorder Medications" highlights the gaps and disparities in the inclusion and reporting of racial and ethnic data in clinical research, using the example of research on attention-deficit/hyperactivity disorder pharmacological treatment. The authors emphasized the underreporting of data on race and ethnicity in randomized controlled trials on attention-deficit/hyperactivity disorder medications and the overrepresentation of White participants. Their thorough analysis serves as a vital call to action for enhancing representativeness and transparency in research, ensuring that findings are both comprehensive and applicable to diverse populations. However, while the intent to improve inclusivity in clinical trials is universally important, implementing this can be challenging, especially when considering the varied legal and cultural landscapes across different countries.
